I’m going to keep my personal views on the coronavirus vaccine to myself, at least until I’ve done more research. In the meantime, here’s a news update that I found interesting.
The following information comes from Clinical Trials Arena.
Clinical trials to assess the COVID-19 vaccine candidate, ChAdOx1 nCoV-19 (AZD1222), has begun in South Africa and Brazil. Developed by the University of Oxford and licensed to AstraZeneca, this vaccine is set to be used on 2,000 healthcare workers in Sao Paulo and 1,000 people in Rio de Janeiro, Brazil. South Africa’s University of Witwatersrand will be working with the University of Oxford and the Oxford Vaccine Group to evaluate a candidate in South Africa. Led by vaccinology professor Shabir Madhi, their trial name is called the Ox1Cov-19 Vaccine VIDA-Trial.
Professor Madhi advised the following:
“This is a landmark moment for South Africa and Africa at this stage of the Covid-19 pandemic. As we enter winter in South Africa and pressure increases on public hospitals, now more than ever we need a vaccine to prevent infection by Covid-19.”
The vaccine candidate is made from the ChAdOx1 virus, which is a weakened and non-replicating version of adenovirus (a virus for the common cold). After it’s injected, the body is expected to develop an immune response to spike glycoprotein and block the entry of SARS-CoV-2 in the cells.
Again, I’m going to keep my personal comments to myself…for now.
To check out the full article, click here. If you have any additional information, feel free to comment below.
Until Next Time…